Poon, E., Mullins, S., Watkins, A., Williams, G. S., Koopmann, J., Di Genova, G., . . . Wilkinson, R. W. (2017). The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment. J Immunother Cancer.
Chicago-стиль цитированияPoon, Edmund, et al. "The MEK Inhibitor Selumetinib Complements CTLA-4 Blockade By Reprogramming the Tumor Immune Microenvironment." J Immunother Cancer 2017.
MLA-цитированиеPoon, Edmund, et al. "The MEK Inhibitor Selumetinib Complements CTLA-4 Blockade By Reprogramming the Tumor Immune Microenvironment." J Immunother Cancer 2017.
Предупреждение: эти цитированмия не могут быть всегда правильны на 100%.